Effect of an emerging treatment for liver cancer
Not Applicable
Completed
- Conditions
- Hepatocellular carcinoma (HCC)Cancer
- Registration Number
- ISRCTN12676151
- Lead Sponsor
- Beijing YouAn Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 144
Inclusion Criteria
1. Histologically confirmed diagnosis of HCC
2. No previous treatment for HCC
3. No contraindications for surgery, liver transplantation, or local ablation
4. No previous treatment with chemotherapy or targeted therapy for HCC
5. No history of radiation therapy for HCC
6. No history of radioembolization for HCC
7. No history of radiofrequency ablation for HCC
8. No history of percutaneous ethanol injection for HCC
Exclusion Criteria
Patients who had received any of the above treatments within 6 months before enrollment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Serum AFP level measured by enzyme-linked immunosorbent assay at baseline and after 3 months and 12 months follow-up<br>2. Tumor morphology measured using multidetector computed tomography (MDCT) or magnetic resonance imaging (MRI) evaluation at baseline and after 3 months and 12 months follow-up
- Secondary Outcome Measures
Name Time Method There are no secondary outcome measures